BeOne Medicines (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Tevimbra for treating adults with resectable non-small cell lung cancer at high risk of recurrence.
The recommendation covers Tevimbra for use with chemotherapy as neoadjuvant treatment and continued as monotherapy as adjuvant treatment.
The drugmaker said the recommendation was based on a phase 3 trial, where the treatment met key goals of event-free survival and major pathologic response at the interim analyses.
Shares of the company were up 2.6% in Monday's premarket activity.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。